Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innate Pharma SA ( (FR:IPH) ) has issued an announcement.
On January 7, 2026, Innate Pharma released its share capital and voting rights structure as of December 31, 2025, reporting 93,719,323 ordinary shares outstanding alongside a small number of preferred shares from 2016 and 2017. The company detailed a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, providing transparency required under French market regulations and offering investors and other market participants an updated view of its equity base and potential threshold crossings.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and target identification, the Marseille-based group is advancing a pipeline of next-generation antibody therapeutics, including the Nectin-4 ADC IPH4502 for solid tumors, the anti-KIR3DL2 antibody lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody co-developed with AstraZeneca for non-small cell lung cancer; it also maintains collaborations with major pharma partners such as Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.
Average Trading Volume: 254,919
Technical Sentiment Signal: Strong Sell
Current Market Cap: €146.5M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.